190 related articles for article (PubMed ID: 24390630)
1. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
2. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Qi WX; Shen F; Qing Z; Xiao-Mao G
Tumour Biol; 2014 Nov; 35(11):10715-22. PubMed ID: 25070487
[TBL] [Abstract][Full Text] [Related]
3. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
Peng L; Bu Z; Zhou Y; Ye X; Liu J; Zhao Q
Tumour Biol; 2014 Sep; 35(9):9419-27. PubMed ID: 24957040
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.
Zhang X; Ran Y; Shao Y; Wang K; Zhu Y
Br J Clin Pharmacol; 2016 Jan; 81(1):33-40. PubMed ID: 26331893
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
[TBL] [Abstract][Full Text] [Related]
6. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Clin Drug Investig; 2014 Apr; 34(4):231-40. PubMed ID: 24493142
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related mortality with aflibercept in cancer patients.
Tabernero J; Hitier S; Derobert E; Van Cutsem E
Eur J Clin Pharmacol; 2014 Oct; 70(10):1269-70. PubMed ID: 25055958
[No Abstract] [Full Text] [Related]
9. Risk of treatment-related mortality with sorafenib in patients with cancer.
Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; Xu F; Wei LX; He J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6681-6. PubMed ID: 24377588
[TBL] [Abstract][Full Text] [Related]
10. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
11. Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
Sher AF; Golshani GM; Wu S
Cancer Invest; 2020 Feb; 38(2):130-138. PubMed ID: 31985314
[No Abstract] [Full Text] [Related]
12. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
Glade Bender J; Blaney SM; Borinstein S; Reid JM; Baruchel S; Ahern C; Ingle AM; Yamashiro DJ; Chen A; Weigel B; Adamson PC; Park JR
Clin Cancer Res; 2012 Sep; 18(18):5081-9. PubMed ID: 22791883
[TBL] [Abstract][Full Text] [Related]
17. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.
Wang Z; Yang X; Wang J; Wang S; Mao X; Li M; Zhao Y; Wang W; Qi X; Wu T
J Cancer Res Ther; 2019; 15(7):1435-1449. PubMed ID: 31939421
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
20. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
